Holen Sie sich die Stockscreener-App
2.59
0.00%
-0.0001
Handel nachbörslich:
2.59
Neuraxis Inc Aktie (NRXS) Neueste Nachrichten
Southside Bancshares, Inc. Announces Transfer of Listing of Common Stock to the New York Stock Exchange - The Manila Times
NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market - GlobeNewswire
IRIDEX (NASDAQ:IRIX) versus NeurAxis (NASDAQ:NRXS) Financial Survey - Defense World
NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024 - The Manila Times
NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation - GlobeNewswire
Neuraxis adjusts equity agreement, secures additional funding - Investing.com India
Creatd (NASDAQ:VOCL) Stock Price Down 4.4% – Should You Sell? - Defense World
Technip Energies (OTCMKTS:THNPY) Trading Up 0.7% – Here’s What Happened - Defense World
Vestas Wind Systems A/S (OTCMKTS:VWSYF) Shares Up 1.2% – Here’s What Happened - Defense World
Zacks Initiates Coverage of NeurAxis With Neutral Recommendation - Yahoo Finance
The Zacks Analyst Blog Highlights Costco Wholesale, Alibaba, GE Aerospace, Applied Energetics and NeurAxis - Yahoo Finance
Top Analyst Reports for Costco Wholesale, Alibaba & GE Aerospace - Yahoo Finance
NeurAxis (NASDAQ:NRXS) Trading Up 6% - Defense World
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - GlobeNewswire
Neuraxis issues shares in equity financing By Investing.com - Investing.com Australia
Neuraxis issues shares in equity financing - Investing.com
Fishers startup prepares to go public - Greenfield Daily Reporter
NeurAxis (NASDAQ:NRXS) Stock Price Down 2.2% - Defense World
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024 - GlobeNewswire
Vagus Nerve Stimulators Market Projected to Witness Huge Growth - openPR
Neuraxis shareholders approve key proposals at annual meeting - Investing.com
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024 - GlobeNewswire
NeurAxis revenue down 5.3% to USD 611.5K in Q2 2024 - Medical Buyer
NeurAxis, Inc. (NRXS) Q2 2024 Earnings Call Transcript - Seeking Alpha
Contrasting Sonova (OTCMKTS:SONVY) & NeurAxis (NASDAQ:NRXS) - Defense World
NRXS Stock Earnings: Neuraxis Reported Results for Q2 2024 - MSN
NeurAxis Reports Second Quarter 2024 Financial Results - GlobeNewswire
NeurAxis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Vagus Nerve Stimulators Market Is Booming Worldwide 2024-2031 | - openPR
NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024 - GlobeNewswire
NeurAxis Gains $3 Million In Financing - MPO-mag
Head to Head Comparison: NeurAxis (NASDAQ:NRXS) vs. Positron (OTCMKTS:POSC) - Defense World
Vagus Nerve Stimulators Market Expected to Expand at a Steady - openPR
NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 - Marketscreener.com
ZUU Co. Ltd. executives purchase Pono Capital two shares worth $390 By Investing.com - Investing.com India
Neuraxis issues stock awards to non-employee directors - Investing.com
Blackstone director Baratta sells over $14 million in company stock By Investing.com - Investing.com UK
Head to Head Survey: NeurAxis (NASDAQ:NRXS) versus Electromed (NYSE:ELMD) - Defense World
NeurAxis (NASDAQ:NRXS) and Cutera (NASDAQ:CUTR) Head-To-Head Analysis - Defense World
NRXSNeurAxis, Inc. Latest Stock News & Market Updates - StockTitan
NeurAxis (NASDAQ:NRXS) Stock Price Down 3.3% - Defense World
Nexalin Technology (NASDAQ:NXL) & NeurAxis (NASDAQ:NRXS) Financial Review - Defense World
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with ... - GlobeNewswire
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure - GlobeNewswire Inc.
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure - Yahoo Finance
Outset Medical (NASDAQ:OM) & NeurAxis (NASDAQ:NRXS) Head-To-Head Analysis - Defense World
Vagus Nerve Stimulators Market to Surpass US$ 1,158.7 Mn by 2031 with CAGR 9.7% - WhaTech
NeurAxis Reports First Quarter 2024 Financial Results - br.ADVFN.com
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store? - MSN
Reviewing NeurAxis (NASDAQ:NRXS) and Outset Medical (NASDAQ:OM) - Defense World
NeurAxis, Inc. (NRXS) Q1 2024 Earnings Call Transcript - Seeking Alpha
NRXS Stock Earnings: Neuraxis Reported Results for Q1 2024 - MSN
5.11%
0.50%
Kapitalisierung:
|
Volumen (24h):